medicament 3004909244
CN → US| HS编码 | 关税税率 | 原产国 | 目的国 | 文档 |
|---|---|---|---|---|
| 3004490030 | 10.0% | CN | US | 官方文档 |
| 3004490040 | 10.0% | CN | US | 官方文档 |
| 3003490000 | 10.0% | CN | US | 官方文档 |
| 3003900190 | 10.0% | CN | US | 官方文档 |
| 3004490050 | 10.0% | CN | US | 官方文档 |
| 3004490070 | 10.0% | CN | US | 官方文档 |
AI分析
💊 Medicament (Drugs/Pharmaceutical Preparations)
🌐 HS Code Reference & Customs Clearance Guide | 2026 Latest Tariff Analysis | Professional Clearance Strategy
📌 I. Product Definition & Classification: What Exactly is "Medicament"?
In international trade, "Medicament" is the standard term for pharmaceutical preparations intended for the therapeutic, preventive, or diagnostic use in humans or animals. These are not raw ingredients (which fall under Chapter 29) nor simple medical devices, but finished dosage forms such as tablets, capsules, injections, ointments, or syrups.
⚠️ Key Distinction:
- Active Pharmaceutical Ingredients (APIs): Raw chemical compounds → Typically classified under Chapter 29.
- Finished Medicaments: Formulated drugs ready for administration (with excipients, packaging, etc.) → Classified under Chapter 30.
- Medical Devices: Tools used for diagnosis/treatment without pharmacological action → Classified under Chapters 85–90.
📦 II. HS Code Classification Details (Based on Provided Data)
The following HS Codes are derived specifically from the provided <DATA> set for "Medicament". All entries carry a Total Tax Rate of 10.0% due to Section 301/IEEPA tariffs.
| HS Code | Summary & Reasoning | Total Tax Rate | Tax Breakdown |
|---|---|---|---|
3004.49.00.30 |
Drug Purpose Match: Directly matches the definition of "Medicament" (pharmaceutical preparation). No material or form conflict. | 10.0% | Base: 0.0% Add-on: 0.0% Section 301/IEEPA: 10% |
3004.49.00.40 |
Direct Correspondence: Product name directly corresponds to the code’s purpose (drug). No material or form conflict. | 10.0% | Base: 0.0% Add-on: 0.0% Section 301/IEEPA: 10% |
3003.49.00.00 |
Alkaloid/Bio-Component Bias: Since the product is a "drug," it leans toward categories containing alkaloids or other active components. | 10.0% | Base: 0.0% Add-on: 0.0% Section 301/IEEPA: 10% |
3003.90.01.90 |
Catch-All Rule: Explicitly stated as "Medicament" for therapeutic/preventive purposes. Classified as a residual/other category. | 10.0% | Base: 0.0% Add-on: 0.0% Section 301/IEEPA: 10% |
3004.49.00.50 |
Purpose Alignment: Product points to "drug"; its purpose aligns completely with therapeutic/preventive definitions of the code. | 10.0% | Base: 0.0% Add-on: 0.0% Section 301/IEEPA: 10% |
3004.49.00.70 |
Clear Therapeutic Use: Explicitly a drug for therapeutic/preventive purposes. No material or form conflicts. | 10.0% | Base: 0.0% Add-on: 0.0% Section 301/IEEPA: 10% |
🔍 Critical Insight:
- All suggested HS Codes belong to Chapter 30 (Pharmaceutical Products).
- The base tariff is 0%, but a mandatory 10% additional tariff (likely under Section 301 or IEEPA for Chinese-origin goods) applies uniformly.
- Codes starting with 3004 are for "Medicaments (other than goods of heading 3002, 3005 or 3006); medicaments consisting of mixed or unmixed products..."
- Codes starting with 3003 are for "Medicaments (other than goods of heading 3002, 3005 or 3006); mixed or unmixed products..."
💰 III. 2026 Latest Tariff Rate Details (Including Additional Taxes)
✅ Applicable Country: United States (US)
✅ Origin: Likely China (CN) – Inferred from the 10% IEEPA/Section 301 tariff structure
✅ Effective Date: Ongoing (as of 2026)
🎯 Universal Tax Structure for All Listed Codes
| Item | Content |
|---|---|
| Base Tariff Rate | 0% (ad valorem) |
| Section 301 / IEEPA Surcharge | +10% (Specifically applied under Clause 122/IEEPA for Chinese pharmaceuticals) |
| Total Effective Tax Rate | 10.0% |
| Tax Calculation | CIF Value × 10% |
| De Minimis Eligibility | ❌ No (Pharmaceuticals are generally restricted from de minimis exemptions under current trade policies) |
| Legal Basis Path | HTSUS: Chapter 30 → Section 301/IEEPA: Clause 122 → 10% Surcharge |
📌 Explanation:
- Base 0%: Standard MFN (Most Favored Nation) rate for pharmaceuticals is often zero or low, depending on the specific subheading.
- 10% Surcharge: This is the critical cost driver. It applies due to trade restrictions (such as Section 301 or specific IEEPA orders) targeting Chinese-origin pharmaceutical products.
- No Base Conflict: Since the base is 0%, the entire financial burden comes from the additional duty.
🛠️ IV. Customs Clearance Practical Advice (Real-World Pitfall Avoidance)
✅ 1. Required Documentation Checklist (Non-Negotiable)
| Document | Must Provide | Explanation |
|---|---|---|
| ✅ Drug Listing & NDC (National Drug Code) | ✔️ | Essential for FDA compliance and accurate HS classification. |
| ✅ Formula/Composition Sheet | ✔️ | Lists active ingredients and excipients to justify Chapter 30 vs. Chapter 29. |
| ✅ FDA Prior Notice | ✔️ | Mandatory for food/drug imports into the US. |
| ✅ Certificate of Analysis (CoA) | ✔️ | Proves potency and purity of the medicament. |
| ✅ Commercial Invoice | ✔️ | Must clearly state "Medicament," dosage form (e.g., tablet, solution), and active ingredient. |
| ✅ Country of Origin Certificate | ✔️ | To determine applicability of the 10% additional tariff. |
| ✅ FDA Import Alert Status Check | ✔️ | Ensure the facility/product is not on FDA Import Alert (Detention Without Physical Examination). |
✅ 2. Declaration Tips (Key Mnemonic)
🔥 "Clear Purpose, Exact Code, No Raw Mix, Tax Hit Hard!"
| Scenario | Correct Declaration | Wrong Practice |
|---|---|---|
| Finished Tablets/Capsules | Use 3004.xxxxxxxx codes (e.g., 3004.49.00.30) |
Mistaking for "Chemicals" (Ch 29) → Higher scrutiny + different tax |
| Mixed/Unmixed Pharmaceuticals | Use 3003.xxxxxxxx if applicable | Vague description "Health Products" → Delays |
| Generic Medicament | Specify generic name (e.g., "Ibuprofen Tablets") | Vague "Pain Relief" → Risk of reclassification |
| Bulk Powder (Active Ingredient) | Likely Chapter 29, NOT Chapter 30 | Misdeclaring API as "Medicament" → Misclassification penalty |
✅ 3. Special Handling
| Situation | Handling Advice |
|---|---|
| Biological Medicaments | Ensure classification under 3002 (not 3004/3003) if applicable; different tax rules may apply. |
| Homeopathic Remedies | Can still be classified under Chapter 30 if for therapeutic use; provide proof of formulation. |
| Veterinary vs. Human | Clearly state use case; mislabeling can lead to FDA vs. USDA jurisdiction conflicts. |
| Sample Shipments | Even samples require FDA Prior Notice and may be subject to the 10% tariff unless properly exempted (rare). |
🌍 V. Global Market Clearance Comparison (2026 Latest)
| Country/Region | Recommended HS Code | Tariff | Certification Requirements | Notes |
|---|---|---|---|---|
| 🇺🇸 USA | 3004.49.00.30 etc. |
10% | FDA Approval/Listing + Prior Notice | High compliance barrier; 10% tariff is fixed. |
| 🇨🇳 China | 3004.90.90 etc. |
Varies | NMPA Registration | Domestic sales require local approval. |
| 🇪🇺 EU | 3004 series |
0% - 4.5% | EMA/GMP + CE Labeling | Generally lower tariffs for finished drugs; strict GMP needed. |
| 🇬🇧 UK | 3004 series |
0% - 4.5% | MHRA Approval | Post-Brexit rules apply; check UK Tariff. |
| 🇯🇵 Japan | 3004 series |
0% - 6% | PMDA Approval | Strict quality standards; low base tariffs. |
📌 Conclusion:
- USA imposes a flat 10% additional tariff on Chinese-origin medicaments regardless of the specific 3003/3004 subheading.
- EU/UK/Japan have lower or zero base tariffs but require stricter regulatory approvals (EMA/MHRA/PMDA).
- Compliance Cost > Tax Cost: In the US, the regulatory hurdle (FDA) is often more significant than the 10% tariff.
📌 VI. Common Errors & Pitfall Guide (Blood & Tears Lessons)
❌ Error 1: Declaring "Active Ingredient Powder" as "Medicament"
👉 Consequence: Misclassification (Chapter 29 vs. 30). If it’s a pure chemical, it may fall under Chapter 29, but if formulated, it’s 30. Wrong code = Seizure.
❌ Error 2: Missing FDA Prior Notice
👉 Consequence: Automatic Detention by FDA and CBP. Goods cannot clear customs until notice is filed.
❌ Error 3: Vague Description "Health Supplement"
👉 Consequence: If the product has a therapeutic claim, it is a Drug, not a supplement. Misdeclaration leads to FDA Warning Letters and potential fines.
❌ Error 4: Ignoring the 10% Tariff in Costing
👉 Consequence: Profit margin erosion. The base is 0%, so the entire 10% is additional cost. Budget accordingly.
✅ Correct Practice:
"Ibuprofen 200mg Tablets, for Human Therapeutic Use, FDA Listed, NDC: 12345-678-90, Model: MED-200"
🎯 VII. Conclusion: Professional Declaration Saves Time & Money!
🎯 Remember the Mantra:
🔹 "Chapter 30 for Formulated Drugs, Chapter 29 for Raw Materials."
🔹 "10% Surcharge is Inevitable for CN Origin; Plan Your Pricing."
🔹 "FDA Prior Notice is Non-Negotiable; No Notice, No Entry."
📌 Pro Tip:
- If you are exporting biologicals (vaccines, blood, etc.), check Heading 3002 instead of 3003/3004, as tax rules differ.
- Always apply for a Binding Ruling with CBP if you are unsure whether your product is a "Drug" or a "Device" or a "Supplement."
- Ensure your supplier provides a Letter of Authorization if you are the exclusive US distributor, to streamline FDA interactions.
📣 Immediate Action:
📞 Consult a Customs Broker specializing in Pharmaceuticals.
📄 Submit FDA Prior Notice at least 2 hours before arrival.
📊 Calculate Landed Cost including the 10% IEEPA tariff.
✨ Professional Clearance Starts with Precise Classification!
💼 Every Dollar of Tax and Every Day of Delay Costs You Market Share!
用户评价
关于 HS 编码归类
协调制度（HS）是由世界海关组织（WCO）制定的国际贸易商品分类标准。全球 200 多个国家采用 HS 系统作为海关关税、贸易统计和进出口监管的基础。
每个 HS 编码遵循以下层级结构：
- 章（2 位）——商品大类（例如：第 84 章：机器和机械设备）
- 品目（4 位）——章内的更具体分类
- 子目（6 位）——国际通用细分，所有 WCO 成员国统一使用
- 本国细分（8-10 位）——各国自行扩展的细分编码，如美国 HTSUS 10 位编码
正确的 HS 编码归类对于顺利通关、准确缴纳关税和遵守贸易法规至关重要。错误归类可能导致海关延误、多缴关税或罚款。
从CN进口到US时，适用的关税税率可能包括：
- 最惠国（MFN）税率——适用于 WTO 成员国的标准关税税率
- 普通税率——适用于无贸易协定国家
- 贸易救济关税——附加关税，如 301 条款（反倾销）、232 条款（国家安全）或反补贴税
本页内容仅供参考。如需正式归类，请咨询当地海关或持牌报关代理。